These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

847 related items for PubMed ID: 21838410

  • 21. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
    Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A.
    Int Clin Psychopharmacol; 2011 Mar; 26(2):75-83. PubMed ID: 21102344
    [Abstract] [Full Text] [Related]

  • 22. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J.
    BMC Psychiatry; 2005 Jan 04; 5():1. PubMed ID: 15631624
    [Abstract] [Full Text] [Related]

  • 23. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, Hong JP, Ruschel S, Raskin J, Colman SA, Harrison GA.
    Psychiatry Clin Neurosci; 2007 Jun 04; 61(3):295-307. PubMed ID: 17472599
    [Abstract] [Full Text] [Related]

  • 24. Time course of depression-symptom improvement during treatment with duloxetine.
    Hirschfeld RM, Mallinckrodt C, Lee TC, Detke MJ.
    Depress Anxiety; 2005 Jun 04; 21(4):170-7. PubMed ID: 16035056
    [Abstract] [Full Text] [Related]

  • 25. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
    Baldwin DS, Loft H, Dragheim M.
    Eur Neuropsychopharmacol; 2012 Jul 04; 22(7):482-91. PubMed ID: 22209361
    [Abstract] [Full Text] [Related]

  • 26. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH, Montgomery SA, Earley WR, Szamosi J, Lazarus A.
    Int Clin Psychopharmacol; 2012 Jan 04; 27(1):27-39. PubMed ID: 22027845
    [Abstract] [Full Text] [Related]

  • 27. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov 04; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

  • 28. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
    Wu WY, Wang G, Ball SG, Desaiah D, Ang QQ.
    Chin Med J (Engl); 2011 Oct 04; 124(20):3260-8. PubMed ID: 22088518
    [Abstract] [Full Text] [Related]

  • 29. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D.
    J Clin Psychiatry; 2013 Apr 04; 74(4):363-9. PubMed ID: 23656841
    [Abstract] [Full Text] [Related]

  • 30. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ.
    Int J Clin Pract; 2007 Aug 04; 61(8):1337-48. PubMed ID: 17627710
    [Abstract] [Full Text] [Related]

  • 31. A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
    Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y, Thase ME.
    J Clin Psychiatry; 2012 Jul 04; 73(7):953-9. PubMed ID: 22901346
    [Abstract] [Full Text] [Related]

  • 32. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.
    J Clin Psychiatry; 2011 Apr 04; 72(4):464-72. PubMed ID: 21527123
    [Abstract] [Full Text] [Related]

  • 33. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan 04; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 34. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
    Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN.
    Depress Anxiety; 2008 Jan 04; 25(7):E1-11. PubMed ID: 17587217
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.
    Depress Anxiety; 2008 Jan 04; 25(3):182-9. PubMed ID: 17311303
    [Abstract] [Full Text] [Related]

  • 36. Management of depression relapse: re-initiation of duloxetine treatment or dose increase.
    Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D.
    J Psychiatr Res; 2006 Jun 04; 40(4):328-36. PubMed ID: 16678205
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of duloxetine 30 mg/d in patients with fibromyalgia: a randomized, double-blind, placebo-controlled study.
    Arnold LM, Zhang S, Pangallo BA.
    Clin J Pain; 2012 Jun 04; 28(9):775-81. PubMed ID: 22971669
    [Abstract] [Full Text] [Related]

  • 38. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
    Cowen PJ, Ogilvie AD, Gama J.
    Curr Med Res Opin; 2005 Mar 04; 21(3):345-56. PubMed ID: 15811202
    [Abstract] [Full Text] [Related]

  • 39. Assessment of depressive symptoms and functional outcomes in patients with major depressive disorder treated with duloxetine versus placebo: primary outcomes from two trials conducted under the same protocol.
    Oakes TM, Myers AL, Marangell LB, Ahl J, Prakash A, Thase ME, Kornstein SG.
    Hum Psychopharmacol; 2012 Jan 04; 27(1):47-56. PubMed ID: 22241678
    [Abstract] [Full Text] [Related]

  • 40. Duloxetine in treatment of anxiety symptoms associated with depression.
    Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ.
    Depress Anxiety; 2003 Jan 04; 18(2):53-61. PubMed ID: 12964171
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.